EP Patent

EP2968291C0 — HSPC-SPARE TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION

Assigned to Pharmacosmos Holding AS · Expires 2025-04-16 · 1y expired

What this patent protects

Patent listed against trilaciclib-dihydrochloride.

Drugs covered by this patent

trilaciclib-dihydrochloride (TRILACICLIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: EP2968291C0
Jurisdiction: EP
Classification: —
Expires: 2025-04-16
Drug substance claim: No
Drug product claim: No
Assignee: Pharmacosmos Holding AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.